Company
Every investor coverage indicates participated in a round Concordia raised.
Companies Concordia acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Dr Karl Roberts | Global Head of Business Development (former) | Brandon BioCatalyst portfolio, Brandon Capital portfolio |
Stories naming Concordia. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Drug developer George Medicines has named Stefan König, previously a senior Takeda executive, as its chief executive, while chief business officer Karl Roberts moves into the chief operating officer role.
George Medicines has named Stefan König, previously a Takeda franchise head, as its new CEO, while Karl Roberts moves from Chief Business Officer to Chief Operating Officer. The company also announced US FDA clearance to begin Phase III trials of GMRx2.